

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
7 July 2005 (07.07.2005)

PCT

(10) International Publication Number
WO 2005/060963 A1

(51) International Patent Classification⁷: **A61K 31/44**,
31/4436, C07D 213/76, 409/12, 401/12, 417/12, C07C
311/37, 311/36, A61P 3/10, 3/04

(21) International Application Number:
PCT/IB2004/004056

(22) International Filing Date: 6 December 2004 (06.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/531,186 19 December 2003 (19.12.2003) US
60/556,921 26 March 2004 (26.03.2004) US

(71) Applicant (for all designated States except US): **PFIZER INC.** [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **EDWARDS, Martin, Paul** [GB/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **JOHNSON, Theodore, Otto, Jr.** [US/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **NAIR, Sajiv, Krishnan** [IN/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **SIU, Michael** [US/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **TAYLOR, Wendy, Dianne** [US/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **CRIPPS, Stephan, James** [US/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **WANG, Yong** [CN/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science

Center Drive, San Diego, CA 92121 (US). **CHENG, Hengmiao** [CA/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US). **SMITH, Christopher, Ronald** [GB/US]; Agouron Pharmaceuticals, Inc., A Pfizer Company, 10777 Science Center Drive, San Diego, CA 92121 (US).

(74) Agents: **FULLER, Grover, F., Jr.** et al.; Pfizer Inc., 201 Tabor Road, Morris Plains, NJ 07950 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:


- with international search report
- with amended claims

(48) Date of publication of this corrected version:
27 October 2005

(15) Information about Correction:
see PCT Gazette No. 43/2005 of 27 October 2005, Section II

[Continued on next page]

(54) Title: BENZENESULFONYLAMINO-PYRIDIN-2-YL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11-BETA-HSD-1) FOR THE TREATMENT OF DIABETES AND OBESITY



(57) Abstract: The present invention relates to compounds with the formula (I), or a pharmaceutically acceptable salt thereof, wherein: R¹ is selected from the group consisting of (C₁-C₆)alkyl, -(CR³R⁴)_i(C₃-C₁₂)cycloalkyl, -(CR³R⁴)_i(C₆-C₁₂)aryl, and -(CR³R⁴)_i(4-10)-membered heterocyclyl; b and k are each independently selected from 1 and 2; j is selected from the group consisting of 0, 1, and 2; t, u, p, q, and v are each independently selected from the group consisting of 0, 1, 2, 3, 4, and 5; T is a (6-10)-membered heterocyclyl containing at least one nitrogen atom; R² is selected from the group consisting of H, (C₁-C₆)alkyl, -(CR³R⁴)_i(C₃-C₁₂)cycloalkyl, -(CR³R⁴)_i(C₆-C₁₂)aryl, and -(CR³R⁴)_i(4-10)-membered heterocyclyl; each R³ and R⁴ is independently selected from H and (C₁-C₆)alkyl, the carbon atoms of T, R¹, R², R³ and R⁴ may each be optionally, substituted by I to 5 R⁵ groups; R⁵ is defined in the claims; The compounds of the present invention are 11 β-hsd-1 inhibitors, and are therefore believed to be useful in the treatment of diabetes, obesity, glaucoma, osteoporosis, cognitive disorders, immune disorders, depression, hypertension, and metabolic diseases.

WO 2005/060963 A1



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.